Effect of Bezafibrate(Bezalip(R))in Patients with Hyperlipidemia.
10.4070/kcj.1989.19.3.497
- Author:
Chee Jeong KIM
;
Young Dae KIM
;
Dong Jin OH
;
Byung Hee OH
;
Myoung Mook LEE
;
Young Bae PARK
;
Yun Shik CHOI
;
Jung Don SEO
;
Young Woo LEE
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Bezafibrate;
Hyperlipidemia
- MeSH:
Bezafibrate;
Cholesterol;
Compliance;
Dyspepsia;
Humans;
Hyperlipidemias*;
Triglycerides
- From:Korean Circulation Journal
1989;19(3):497-502
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
41 patients with hyperlipidemia(Serum cholesterol > or =260mg% or triglyceride> or =200mg%) were treated for 12 weeks each with either Bezafibrate(200mg t.i.d.)(n=23) or placebo(n=18) in a randomized trial. Compared with placebo, Bezafibrate was more effective in lowing total cholesterol(287+/-63 to 244+/-32 mg%, P<0.01), LDL-cholesterol(183+/-39 to 153 +/-25mg%, P<0.01) and the LDL/HDL ratio(4.7+/-2.9 to 3.4+/-1.3, P<0.05). There was also a marked reduction in serum triglyceride(307+/-295 to 218+/-167mg%, P<0.05) as well as a significant increase in HDL-cholesterol(43+/-12 to 48+/-12mg%, P<0.05). Compliance or tolerance to both Bezafibrate and placebo was good. No significant side effects except one case, who complained of mild indigestion, were observed. Therefore, Bezafibrate seemed to be effective in lowing serum total cholesterol, LDL-cholestrol, triglyceride and in increasing in HDL-cholesterol without significant side effect.
